VVIVEbiotech — Series A (estimated) · €3.5M
A €3.5M capital increase co-led by Inveready Biotech III and Easo Ventures, with most existing shareholders taking part, to add three cleanrooms and raise production capacity 30-fold. Reports called it the company's second raise, after about €1M a year earlier (date and investors not reported), bringing total capital to €7.1M.
LeadInveready Biotech III, Easo Ventures
RoundSeries A (estimated)
Announced9 Sep 2019
CitySan Sebastián
SectorHealthtech & Bio · Biotech / Cell and gene therapy CDMO
Source
W
W
